BioSpace News Archive

Strides in the clinical nutrition market are interspersed by continuous research in improving health outcomes by developing nutrient intake profiles to meet dietary requirements in populations.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced an interview with CEO Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program.

If approved, KALYDECO® (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age

Zyla Life Sciences, a commercial stage life sciences company, announced that its 2020 first quarter financial results will be released on May 15, 2020.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the Company will participate in the upcoming STRH Life Sciences Summit Virtual Series. SeaSpine is scheduled to participate in a fireside chat on Thursday, May 7, 2020 at 11:00am ET. A live and archived webcast of the event will be available from the Investor Relations page of

TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), has found that patients aged 30 to 50 with COVID-19 are twice as likely to suffe

Implementation has enabled Obsidian to remain on track to meet development targets, while maintaining a safe working environment for all employees

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 Virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020 . In consideration of the health and well-being of our stockholders, directors and employees, and in compliance with federal,

GlycoMimetics, Inc., Inc. (Nasdaq: GLYC) today reported its financial results for the first quarter ended March 31, 2020 and highlighted recent company events. Cash and cash equivalents at March 31, 2020 were $154.8 million.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486, an investigational oral hypomethylating agent, for the maintenance treatment of adult patients with acute myeloid leukemia (AML)